XTL to Present at the Arch Investment Conference
05 September 2007 - 5:11PM
PR Newswire (US)
VALLEY COTTAGE, New York, September 5 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL), a
biopharmaceutical company engaged in the acquisition, development
and commercialization of therapeutics for the treatment of unmet
medical needs, particularly neuropathic pain and hepatitis C, today
announced today that Ron Bentsur, the Company's Chief Executive
Officer, is scheduled to present at the Arch Investment Conference.
Mr. Bentsur will present an overview of the Company including a
discussion of Bicifadine, the Company's late-stage clinical
compound for the treatment of neuropathic pain. Mr. Bentsur's
presentation will take place, tomorrow, Thursday, September 6, 2007
at 11:30 pm Eastern Daylight Time, at the Warwick Hotel in New York
City. A live audio webcast of Mr. Bentsur's presentation will be
available at:
http://www.informedinvestors.com/VC/ClientPage.asp?ID=45356. An
archived version of the webcast will be available following the
conclusion of the live presentation. ABOUT XTL BIOPHARMACEUTICALS
LTD. XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the
development of therapeutics for the treatment of neuropathic pain
and hepatitis C. XTL is developing Bicifadine, a serotonin and
norepinephrine reuptake inhibitor, for the treatment of diabetic
neuropathic pain. XTL is also developing several novel pre-clinical
hepatitis C small molecule inhibitors. XTL also has an active
in-licensing and acquisition program designed to identify and
acquire additional drug candidates. XTL is publicly traded on the
NASDAQ, London, and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(LSE:XTL)(TASE:XTL). Contact: Ron Bentsur Chief
Executive Officer Tel: +1-845-267-0707, ext. 225 DATASOURCE: XTL
Biopharmaceuticals Ltd CONTACT: Contact: Ron Bentsur, Chief
Executive Officer, Tel: +1-845-267-0707, ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024